HILTON HEAD, SC, Oct. 18 (GenomeWeb News) - The Wellcome Trust Sanger Institute purchased a 454 sequencing platform as early as this summer, according to a 454 official.
The Sanger placement is noteworthy because the institute is a participant in an alpha-production program with 454 rival Solexa.
454 has formally disclosed two other placements --- at the Joint Genome Institute, which bought an instrument in August, and the Broad Institute, which installed one in March, which happened to be 454's first paid placement, the company said on its web site.
A 454 official, speaking off the record at the Genomes, Medicine and the Environment Conference held here this week, reckoned the CuraGen subsidiary has so far installed around 14 instruments worldwide, including one at Washington University. He asked not to be named because the company prefers media inquiries be forwarded to a designated spokesperson.
A CuraGen spokesperson, however, would only confirm the placement of five instruments through the end of June, the company's most recent fiscal quarter. The spokesperson added that the firm did continue to sell additional instruments before its partner Roche Applied Science officially announced the commercial launch of the system in early October.